Cinnarizine + DimenhydrinateThird Party Manufacturing in India

The fixed-dose combination of Cinnarizine and Dimenhydrinate provides a complementary dual mechanism for the treatment of vertigo and associated symptoms. Cinnarizine acts as a calcium channel blocker and histamine H1 receptor antagonist. By inhibiting calcium influx into vestibular hair cells, it reduces the excitability of the peripheral vestibular system and suppresses abnormal neural signals that trigger vertigo. It also improves labyrinthine microcirculation through cerebral vasodilation and enhanced erythrocyte deformability. Dimenhydrinate is the chlorotheophylline salt of diphenhydramine and functions primarily as a potent H1 receptor antagonist with additional anticholinergic properties. It acts centrally on the vomiting centre and the chemoreceptor trigger zone in the medulla oblongata, suppressing nausea and the emetic response that frequently accompanies vertigo. The combination of these two agents produces synergistic efficacy: Cinnarizine targets the vestibular source of the vertigo signal itself, while Dimenhydrinate addresses the secondary vegetative symptoms of nausea and vomiting. Clinical studies have demonstrated that the fixed combination is superior to either agent used alone, with faster symptom relief and a more favourable tolerability profile. The combination also exhibits a lower incidence of extrapyramidal side effects compared to Cinnarizine monotherapy at higher doses, likely due to the dose-sparing effect of the dual mechanism.

Therapeutic Uses

Cinnarizine + Dimenhydrinate combination is prescribed for the treatment of:

• Vestibular Vertigo: First-line therapy for acute and recurrent vertigo of peripheral origin including Menieres disease, vestibular neuronitis, and labyrinthitis.
• Motion Sickness: Highly effective for prophylaxis and treatment of nausea, vomiting, and dizziness during travel.
• Meniere's Disease: Reduces the frequency, duration, and intensity of vertiginous attacks along with associated tinnitus and aural fullness.
• Vestibular Migraine: Used as adjunctive therapy for vertiginous episodes associated with migrainous vertigo.
• Nausea and Vomiting of Vestibular Origin: Controls the autonomic symptoms that accompany balance disorders.

Why Manufacturers Choose Cinnarizine + Dimenhydrinate

This fixed-dose combination is one of the highest-prescribed antivertigo products in the Indian pharmaceutical market, supported by strong evidence from multiple randomised controlled trials demonstrating superior efficacy over monotherapy. The combination addresses a large and growing patient population, with vertigo affecting approximately 5% of adults globally and prevalence rates increasing with age. For Indian third-party manufacturers, the mouth dissolving tablet formulation offers a differentiated product that commands better pricing and physician preference. Both active ingredients are well-characterised, with stable API supply chains and established manufacturing processes. The molecule combination presents excellent opportunities for PCD franchise distribution, with high prescription volumes from ENT specialists, neurologists, and general practitioners. Cinnarizine + Dimenhydrinate manufacturing aligns well with WHO-GMP certified facilities aiming to build a presence in the neurology segment.